SLC5A2 and type 2 diabetes mellitus: Dapagliflozin. Dapagliflozin and empagliflozin are sodium-glucose cotransporter 2 (SGLT-2) inhibitors approved by the FDA as oral hypoglycemic drugs in T2DM patients [83].